4D Molecular Therapeutics (NASDAQ:FDMT) & Apogee Therapeutics (NASDAQ:APGE) Financial Comparison

Apogee Therapeutics (NASDAQ:APGE) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Volatility and Risk

Apogee Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500.

Valuation and Earnings

This table compares Apogee Therapeutics and 4D Molecular Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$83.99 million	($5.25)	-9.91
4D Molecular Therapeutics	$20.22 million	20.59	-$100.84 million	($2.30)	-3.48

Apogee Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Apogee Therapeutics and 4D Molecular Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	0	0	6	0	3.00
4D Molecular Therapeutics	0	1	8	0	2.89

Apogee Therapeutics currently has a consensus price target of $78.50, suggesting a potential upside of 50.85%. 4D Molecular Therapeutics has a consensus price target of $47.14, suggesting a potential upside of 488.55%. Given 4D Molecular Therapeutics’ higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Apogee Therapeutics.

Institutional & Insider Ownership

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Apogee Therapeutics and 4D Molecular Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-20.05%	-19.33%
4D Molecular Therapeutics	N/A	-24.06%	-22.52%

Summary

4D Molecular Therapeutics beats Apogee Therapeutics on 7 of the 12 factors compared between the two stocks.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.